Table 3.
Baseline characteristics of all patients 1.
| Diagnosis | Age | PS 2 | Stage | Pre-RT Treatment 3 |
Chemotherapy 4 | Post-RT Treatment 3 |
Pre-RT Hb (g/dL) | Pre-RT Alb (g/dL) |
|---|---|---|---|---|---|---|---|---|
| Esophageal cancer | 58 | 0 | IIB | OP | Weekly CDDP (30) | - | 12.6 | 3.5 |
| Esophageal cancer | 52 | 0 | IIIC | - | Weekly CDDP (20) + Taxol (50) | OP | 13.7 | 4 |
| HCC | 31 | 0 | IIIC | OP | - | - | 10.6 | 4.6 |
1 Abbreviations: PS, performance status; RT, radiotherapy; Hb, hemoglobin; Alb, albumin; OP, operation; CDDP, cisplatin; HCC, hepatocellular carcinoma; ECOG, Eastern Cooperative Oncology Group; CCRT, concurrent chemoradiotherapy. 2 The performance status was graded with ECOG score, in which grade 0 represented fully active. 3 Two patients with esophageal cancer received esophagectomy and lymph node dissection. The patient with HCC received adjuvant RT to the surgical bed for diaphragm and right adrenal gland invasion after segmental hepatectomy and right adrenal gland resection. 4 The patient with esophageal cancer treated with adjuvant CCRT received weekly cisplatin (30 mg/m2), and the other one treated with neoadjuvant CCRT received weekly cisplatin (20 mg/m2) and paclitaxel (50 mg/m2).